403 related articles for article (PubMed ID: 26954482)
41. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
Brugts JJ; van Vark L; Akkerhuis M; Bertrand M; Fox K; Mourad JJ; Boersma E
Int J Cardiol; 2015 Feb; 181():425-9. PubMed ID: 25569271
[TBL] [Abstract][Full Text] [Related]
42. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
Liu Y; Ma X; Zheng J; Jia J; Yan T
BMC Nephrol; 2017 Jun; 18(1):206. PubMed ID: 28666408
[TBL] [Abstract][Full Text] [Related]
43. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
Mercier K; Smith H; Biederman J
Prim Care; 2014 Dec; 41(4):765-78. PubMed ID: 25439533
[TBL] [Abstract][Full Text] [Related]
44. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases.
Gerc V; Buksa M
Med Arh; 2010; 64(5):295-9. PubMed ID: 21287956
[TBL] [Abstract][Full Text] [Related]
45. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
; Lawler PR; Derde LPG; van de Veerdonk FL; McVerry BJ; Huang DT; Berry LR; Lorenzi E; van Kimmenade R; Gommans F; Vaduganathan M; Leaf DE; Baron RM; Kim EY; Frankfurter C; Epelman S; Kwan Y; Grieve R; O'Neill S; Sadique Z; Puskarich M; Marshall JC; Higgins AM; Mouncey PR; Rowan KM; Al-Beidh F; Annane D; Arabi YM; Au C; Beane A; van Bentum-Puijk W; Bonten MJM; Bradbury CA; Brunkhorst FM; Burrell A; Buzgau A; Buxton M; Cecconi M; Cheng AC; Cove M; Detry MA; Estcourt LJ; Ezekowitz J; Fitzgerald M; Gattas D; Godoy LC; Goossens H; Haniffa R; Harrison DA; Hills T; Horvat CM; Ichihara N; Lamontagne F; Linstrum KM; McAuley DF; McGlothlin A; McGuinness SP; McQuilten Z; Murthy S; Nichol AD; Owen DRJ; Parke RL; Parker JC; Pollock KM; Reyes LF; Saito H; Santos MS; Saunders CT; Seymour CW; Shankar-Hari M; Singh V; Turgeon AF; Turner AM; Zarychanski R; Green C; Lewis RJ; Angus DC; Berry S; Gordon AC; McArthur CJ; Webb SA
JAMA; 2023 Apr; 329(14):1183-1196. PubMed ID: 37039790
[TBL] [Abstract][Full Text] [Related]
46. Reducing cardiorenal risk through combination therapy with a direct renin inhibitor.
Rastogi A; Rashid M; Wright RF
J Clin Hypertens (Greenwich); 2011 Nov; 13(11):848-55. PubMed ID: 22051431
[TBL] [Abstract][Full Text] [Related]
47. Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?
Mallat SG
Cardiovasc Diabetol; 2013 Jul; 12():108. PubMed ID: 23866091
[TBL] [Abstract][Full Text] [Related]
48. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
[TBL] [Abstract][Full Text] [Related]
49. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis.
Caldeira D; Alarcão J; Vaz-Carneiro A; Costa J
BMJ; 2012 Jul; 345():e4260. PubMed ID: 22786934
[TBL] [Abstract][Full Text] [Related]
50. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
[TBL] [Abstract][Full Text] [Related]
51. Renin-angiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan.
Tang CH; Chen TH; Wang CC; Hong CY; Huang KC; Sue YM
Eur J Heart Fail; 2013 Oct; 15(10):1194-202. PubMed ID: 23671265
[TBL] [Abstract][Full Text] [Related]
52. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
[TBL] [Abstract][Full Text] [Related]
53. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[TBL] [Abstract][Full Text] [Related]
54. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
[TBL] [Abstract][Full Text] [Related]
55. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
56. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
57. Benefits of SGLT2 inhibitors combining with renin-angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysis.
Liu T; Li R; Wang X; Gao X; Zhang X
Med Clin (Barc); 2022 Jul; 159(2):65-72. PubMed ID: 34872768
[TBL] [Abstract][Full Text] [Related]
58. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.
Shih CJ; Chen HT; Chao PW; Kuo SC; Li SY; Yang CY; Tarng DC; Ou SM; Chen YT
J Hypertens; 2016 Mar; 34(3):567-74; discussion 575. PubMed ID: 26703918
[TBL] [Abstract][Full Text] [Related]
59. The renin-angiotensin system: the role of inhibitors, blockers, and genetic polymorphisms in the treatment and prevention of heart failure.
Hebert PR; Foody JM; Hennekens CH
Curr Vasc Pharmacol; 2003 Mar; 1(1):33-9. PubMed ID: 15320851
[TBL] [Abstract][Full Text] [Related]
60. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease.
Baker WL; Coleman CI; Kluger J; Reinhart KM; Talati R; Quercia R; Phung OJ; White CM
Ann Intern Med; 2009 Dec; 151(12):861-71. PubMed ID: 20008762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
